Document Detail

Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise.
MedLine Citation:
PMID:  12006445     Owner:  NLM     Status:  MEDLINE    
STUDY OBJECTIVES: Aerosolized iloprost, a stable prostacyclin analog, improves functional capacity even in patients with pulmonary hypertension who did not show a vigorous hemodynamic response after iloprost inhalation at rest. We therefore speculated that aerosolized iloprost elicits more beneficial effects on pulmonary hemodynamics during exercise than at rest. DESIGN AND SETTING: A prospective, open, uncontrolled study at a university hospital. PATIENTS: Sixteen patients with primary or secondary pulmonary hypertension. INTERVENTIONS: Right-heart catheterization at rest and during exercise before and after the inhalation iloprost, 14 to 28 microg. RESULTS: Before iloprost treatment, exercise increased mean (+/- SD) pulmonary artery pressure (PAPm) from 45 +/- 8 to 70 +/- 13 mm Hg, cardiac output from 3.7 +/- 1.0 to 5.8 +/- 2.4 L/min, and pulmonary vascular resistance (PVR) from 904 +/- 322 to 1,013 +/- 432 (each p < 0.05). After recovery, iloprost reduced PAPm from 44 +/- 8 to 41 +/- 6 mm Hg, increased cardiac output from 3.7 +/- 1.0 to 4.9 +/- 1.4 L/min, and lowered PVR from 902 +/- 350 to 636 +/- 248 dyne x s x cm(-5) (each p < 0.05). During exercise after iloprost, PAPm increased to 57 +/- 8 mm Hg, cardiac output to 7.0 +/- 3.0 L/min, and PVR to 673 +/- 279 dyne x s x cm(-5) (each p < 0.05 vs first exercise test). Systemic BP was not altered significantly by iloprost treatment during exercise. CONCLUSIONS: Aerosolized iloprost treatment exerts more favorable effects on pulmonary hemodynamics during exercise than at rest. These findings explain the functional improvement observed in patients with pulmonary hypertension who show only a moderate pulmonary vasodilatory response during iloprost inhalation at rest. Whether these beneficial effects have prognostic significance needs to be elucidated by further study.
Friedrich C Blumberg; Günter A J Riegger; Michael Pfeifer
Related Documents :
9360565 - Restraint position and positional asphyxia.
10913985 - Pulmonary function after exercise with special emphasis on diffusion capacity.
9698955 - Intrathoracic and pulmonary blood volume during co2-pneumoperitoneum in humans.
8993725 - Exercise physiology.
8174435 - Strenuous exercise decreases motility and cross-sectional area of human gastric antrum....
7215715 - Studies on pancreatic stones. i. in vitro dissolution.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Chest     Volume:  121     ISSN:  0012-3692     ISO Abbreviation:  Chest     Publication Date:  2002 May 
Date Detail:
Created Date:  2002-05-13     Completed Date:  2002-06-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1566-71     Citation Subset:  AIM; IM    
Department of Internal Medicine II, University of Regensburg, Regensburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Blood Pressure / drug effects
Cardiac Output / drug effects
Exercise Test*
Heart Catheterization
Heart Rate / drug effects
Hemodynamics / drug effects*
Hypertension, Pulmonary / drug therapy*,  physiopathology
Iloprost / administration & dosage*
Middle Aged
Prospective Studies
Pulmonary Artery
Pulmonary Circulation / drug effects
Vascular Resistance / drug effects
Vasodilator Agents / administration & dosage*
Reg. No./Substance:
0/Aerosols; 0/Vasodilator Agents; 78919-13-8/Iloprost

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension...
Next Document:  Oscillatory ventilation during exercise in patients with chronic heart failure: clinical correlates ...